Literature DB >> 30475228

Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.

Ming Chen1, Jiangwen Zhang2, Alice H Berger1, Moussa S Diolombi1, Christopher Ng1, Jacqueline Fung1, Roderick T Bronson3, Mireia Castillo-Martin4,5, Tin Htwe Thin4, Carlos Cordon-Cardo4, Robin Plevin6, Pier Paolo Pandolfi1.   

Abstract

Recurrent broad-scale heterozygous deletions are frequently observed in human cancer. Here we tested the hypothesis that compound haploinsufficiency of neighboring genes at chromosome 8p promotes tumorigenesis. By targeting the mouse orthologs of human DOK2 and DUSP4 genes, which were co-deleted in approximately half of human lung adenocarcinomas, we found that compound-heterozygous deletion of Dok2 and Dusp4 in mice resulted in lung tumorigenesis with short latency and high incidence, and that their co-deletion synergistically activated MAPK signaling and promoted cell proliferation. Conversely, restoration of DOK2 and DUSP4 in lung cancer cells suppressed MAPK activation and cell proliferation. Importantly, in contrast to downregulation of DOK2 or DUSP4 alone, concomitant downregulation of DOK2 and DUSP4 was associated with poor survival in human lung adenocarcinoma. Therefore, our findings lend in vivo experimental support to the notion that compound haploinsufficiency, due to broad-scale chromosome deletions, constitutes a driving force in tumorigenesis.

Entities:  

Keywords:  Cancer; Genetics; Molecular genetics; Mouse models; Oncology

Mesh:

Substances:

Year:  2018        PMID: 30475228      PMCID: PMC6307955          DOI: 10.1172/JCI99699

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism.

Authors:  Yanyan Cai; Jonathan Crowther; Tibor Pastor; Layka Abbasi Asbagh; Maria Francesca Baietti; Magdalena De Troyer; Iria Vazquez; Ali Talebi; Fabrizio Renzi; Jonas Dehairs; Johannes V Swinnen; Anna A Sablina
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

2.  Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer.

Authors:  I I Wistuba; C Behrens; A K Virmani; S Milchgrub; S Syed; S Lam; B Mackay; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

3.  Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.

Authors:  Yu Liu; Chong Chen; Zhengmin Xu; Claudio Scuoppo; Cory D Rillahan; Jianjiong Gao; Barbara Spitzer; Benedikt Bosbach; Edward R Kastenhuber; Timour Baslan; Sarah Ackermann; Lihua Cheng; Qingguo Wang; Ting Niu; Nikolaus Schultz; Ross L Levine; Alea A Mills; Scott W Lowe
Journal:  Nature       Date:  2016-03-16       Impact factor: 49.962

4.  Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.

Authors:  Hirokazu Okayama; Takashi Kohno; Yuko Ishii; Yoko Shimada; Kouya Shiraishi; Reika Iwakawa; Koh Furuta; Koji Tsuta; Tatsuhiro Shibata; Seiichiro Yamamoto; Shun-ichi Watanabe; Hiromi Sakamoto; Kensuke Kumamoto; Seiichi Takenoshita; Noriko Gotoh; Hideaki Mizuno; Akinori Sarai; Shuichi Kawano; Rui Yamaguchi; Satoru Miyano; Jun Yokota
Journal:  Cancer Res       Date:  2011-11-11       Impact factor: 12.701

5.  Identification of DOK genes as lung tumor suppressors.

Authors:  Alice H Berger; Masaru Niki; Alessandro Morotti; Barry S Taylor; Nicholas D Socci; Agnes Viale; Cameron Brennan; Janos Szoke; Noriko Motoi; Paul B Rothman; Julie Teruya-Feldstein; William L Gerald; Marc Ladanyi; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2010-02-07       Impact factor: 38.330

6.  MAP kinase phosphatase-2 plays a critical role in response to infection by Leishmania mexicana.

Authors:  Mashael S Al-Mutairi; Laurence C Cadalbert; H Adrienne McGachy; Muhannad Shweash; Juliane Schroeder; Magdalena Kurnik; Callum M Sloss; Clare E Bryant; James Alexander; Robin Plevin
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

7.  A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions.

Authors:  Wen Xue; Thomas Kitzing; Stephanie Roessler; Johannes Zuber; Alexander Krasnitz; Nikolaus Schultz; Kate Revill; Susann Weissmueller; Amy R Rappaport; Janelle Simon; Jack Zhang; Weijun Luo; James Hicks; Lars Zender; Xin Wei Wang; Scott Powers; Michael Wigler; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

8.  Recurrent hemizygous deletions in cancers may optimize proliferative potential.

Authors:  Nicole L Solimini; Qikai Xu; Craig H Mermel; Anthony C Liang; Michael R Schlabach; Ji Luo; Anna E Burrows; Anthony N Anselmo; Andrea L Bredemeyer; Mamie Z Li; Rameen Beroukhim; Matthew Meyerson; Stephen J Elledge
Journal:  Science       Date:  2012-05-24       Impact factor: 47.728

9.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Authors:  D Chitale; Y Gong; B S Taylor; S Broderick; C Brennan; R Somwar; B Golas; L Wang; N Motoi; J Szoke; J M Reinersman; J Major; C Sander; V E Seshan; M F Zakowski; V Rusch; W Pao; W Gerald; M Ladanyi
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

10.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

View more
  6 in total

1.  miR‑122‑5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression.

Authors:  Ning Hu; Yanhua Tian; Yanmei Song; Leilei Zang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 2.  Introduction to DOK2 and its potential role in cancer.

Authors:  P Sun; R Li; Y Meng; S Xi; Q Wang; X Yang; X Peng; J Cai
Journal:  Physiol Res       Date:  2021-09-10       Impact factor: 1.881

3.  ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling.

Authors:  Samantha A Hutchinson; Priscilia Lianto; Hanne Roberg-Larsen; Sebastiano Battaglia; Thomas A Hughes; James L Thorne
Journal:  Nutrients       Date:  2019-11-01       Impact factor: 5.717

4.  Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors.

Authors:  Yongjun Guan; Man Li; Zhendong Qiu; Junhui Xu; Yichao Zhang; Ning Hu; Xuanzhe Zhang; Wenyi Guo; Jingping Yuan; Qiao Shi; Weixing Wang
Journal:  J Adv Res       Date:  2021-06-12       Impact factor: 10.479

5.  Identification of Melanoma Subsets Based on DNA Methylation Sites and Construction of a Prognosis Evaluation Model.

Authors:  Li Tengda; Qian Cheng; Sun Yi
Journal:  J Oncol       Date:  2022-10-11       Impact factor: 4.501

Review 6.  Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.

Authors:  Dylan A Farnsworth; Yankuan T Chen; Georgia de Rappard Yuswack; William W Lockwood
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.